“If we're soon going to be spending $100 billion a year, we'd better have treatments that work over a long period of time against diseases that are important today and will be more important tomorrow. If we don't know those conditions are satisfied, we can't judge whether we're getting our money's worth,”
“[Part of this enthusiasm has stemmed from recent scientific advances, especially the completion of the human genome.] That pushed us in the 1990s to do what became at that point technologically feasible, ... It added to the momentum.”
“On the commercial side, clearly all of the three major types of companies -- traditional pharmaceutical companies, biotechnology companies and medical device companies -- view health and medicine as a growing market,”
“We've seen growth and a real doubling of funding in all sectors. The proportions are really unchanged over the decade, with roughly 60 percent coming from industry and the remainder coming from government and foundations.”
“[Still,] the doubling over a decade of total spending by U.S. public and private research sponsors in real, inflation-adjusted terms should be reassuring to those who fear that financial sponsorship for research is not paralleling scientific opportunity, ... It is also reassuring that spending on health and biomedical science research by companies and government is not following reductions in research and development in other industries or reduced support for other areas of science.”
